Trials / Completed
CompletedNCT01780519
The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The investigators' goal is to determine if certain tests of memory and attention, performed while sleepiness is induced by a single dose of lorazepam, can predict whether or not an individual is at risk for developing Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lorazepam | single dose of 1 mg lorazepam |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2013-01-31
- Last updated
- 2016-11-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01780519. Inclusion in this directory is not an endorsement.